AMT-130 Breakthrough: 75% Slower Huntington's | AcademicJobs UK
NIHR-backed AMT-130 trial at UCL and Cardiff shows 75% slower Huntington's progression, marking a historic advance in gene therapy research.
No reviews yet. Be the first to rate Liam!
Professor Liam Gray, also known as William Gray, serves as Professor of Functional Neurosurgery in the School of Medicine at Cardiff University, within the Neuroscience and Mental Health Innovation Institute. He holds the position of director of the Health and Care Research Wales funded BRAIN Unit and leads the Advanced Neurotherapies Centre. His clinical and research work focuses on epilepsy, the hippocampus, learning and memory, with particular emphasis on imaging techniques to understand seizure origins and cognitive dysfunction in epilepsy patients. This includes intracranial EEG recordings, imaging of white matter fibre streams, grey matter structure and microstructure, and functional MRI studies.
Professor Gray undertakes clinical research involving advanced therapies for neurodegenerative conditions such as Huntington's disease and Parkinson's disease, including gene therapy trials and cell replacement approaches. He has contributed to studies on the effectiveness of treatments like fluoxetine for memory and learning impairments in mesial temporal lobe epilepsy, as well as protocols for fetal cell transplants in Huntington's disease. As an honorary consultant neurosurgeon at the University Hospital of Wales, he has performed pioneering procedures, including the first robot-assisted epilepsy surgery in Wales. His appointments and leadership roles underscore his contributions to neuroscience research and clinical innovation at Cardiff University, where his work supports trials in advanced therapies for brain disorders.
Professional Email: null
NIHR-backed AMT-130 trial at UCL and Cardiff shows 75% slower Huntington's progression, marking a historic advance in gene therapy research.